This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: Q91.4 | Special Copayment Reduction: V160 | Re-registration cycle: 5 years |
| B. Synonyms | None |
| C. Adult onset | Adult onset: none — Patau syndrome has an extremely high fatality around the time of birth, so survival to adulthood is rare. It is a congenital multiple malformation syndrome with a clear clinical picture from birth. |
| 1. History | 1960 first described by Klaus Patau. Named Patau syndrome, trisomy 13. |
| 2. Causes | 47,+13 karyotype from meiotic nondisjunction (about 80%). Advanced maternal age is the main risk factor. |
| 3. Genetics | 47,XX,+13 or 47,XY,+13. Mostly sporadic. Translocation type (Q91.6) about 10~15%. |
| 4. General epidemiology | About 1/5,000~1/12,000 live births. Rarer than trisomy 18. Correlated with advanced maternal age. |
| 5. Pathophysiology | Trisomy of chromosome 13 from meiotic nondisjunction → causes widespread abnormalities of forebrain and facial development. |
| 6. Symptoms | Holoprosencephaly, microphthalmia/anophthalmia, cleft palate, polydactyly, cardiac malformations, renal malformations. |
| 7. Signs | Midline facial malformation, scalp defect, polydactyly, microphthalmia, heart murmur, microcephaly. |
| 8. Screening | Prenatal ultrasound (detection of holoprosencephaly and midline facial abnormalities), serum screening, cfDNA (NIPT). |
| 9. Diagnosis | Karyotype analysis (G-banding). Distinguishing translocation type from meiotic nondisjunction type is essential. Parental karyotype analysis. |
| 10. Treatment | No curative treatment. Multidisciplinary palliative care. Individualized supportive care according to cardiac and brain malformations. |
| 11. Prognosis | 1-year survival about 5~10%. Median survival about 7~10 days. Prognosis worse than trisomy 18. |
| 12. Prevention | Prenatal screening, awareness of advanced maternal age, PGT-T possible for translocation type after carrier identification. |
| 13. References | Patau K (1960) and 9 others. |
Trisomy 13 was first described in 1960 by the American geneticist Klaus Patau (1908~1975). Patau confirmed by karyotype analysis that chromosome 13 was present in three copies in newborns with facial malformations, holoprosencephaly, polydactyly, and cardiac malformations, and published it in Chromosoma in 1960. The disease is also called Patau syndrome after its describer.
Edwards syndrome (trisomy 18) was described in the same year, so the descriptions of the two diseases were made almost simultaneously. With the spread of karyotyping in the 1960s, data accumulated on the detailed clinical characteristics, subtype classification, and natural history of Patau syndrome. In particular, translocation-type Patau syndrome accounts for as much as about 10~15% of all trisomy 13, and this large difference from translocation-type Edwards syndrome (about 1~2%) was noted early.
As it became known that chromosome 13 is an acrocentric chromosome and therefore a major participant in Robertsonian translocations, the clinical practice of systematically screening for balanced Robertsonian translocation carriers in families with Patau syndrome was established. The most common Robertsonian translocation is rob(13;14).
With advances in prenatal screening technology (ultrasound since the 1980s, serum screening since the 1990s, NIPT since the 2010s), the prenatal diagnosis rate of Patau syndrome has improved greatly. NIPT shows high sensitivity for Patau syndrome (trisomy 13) similar to that for trisomy 18.
In Korea, Patau syndrome is included in rare disease special copayment reduction V160, and together with Down syndrome and Edwards syndrome it is included among the major trisomy syndromes targeted for prenatal screening and diagnosis. The complete form of trisomy 13 (meiotic nondisjunction, Q91.4) is the most common subtype of Patau syndrome, accounting for about 80% of the total.
Trisomy 13 meiotic nondisjunction type (Q91.4) is an aneuploid chromosomal abnormality in which chromosome 13 is present in three copies (47,+13) as a result of meiotic nondisjunction during gamete formation. About 80% of all Patau syndrome arises by this mechanism. The remainder are Robertsonian translocation type (about 10~15%, Q91.6), mosaic type (about 5%, Q91.5), unclassified type (Q91.7), and so on.
The mechanism of meiotic nondisjunction is similar to that of the meiotic nondisjunction type of trisomy 18. Chromosome 13 undergoes a segregation error at the level of sister chromatids or homologous chromosomes, forming a diploid gamete. According to molecular genetic studies, the proportion of maternal origin in trisomy 13 is lower than in trisomy 18 (maternal 90~95%), with about 70~80% of maternal origin and the remaining 20~30% of paternal origin. This means that the proportion of paternal nondisjunction is relatively high in trisomy 13, suggesting that paternal germ cell nondisjunction should be considered in addition to advanced maternal age.
The most important risk factor is advanced maternal age. The incidence rises sharply in mothers aged 35 or older, and when maternal-origin nondisjunction is the main cause, the advanced maternal age effect operates strongly. For paternal nondisjunction, an independent effect of paternal age has been suggested in small studies, but the evidence is insufficient.
Environmental factors: there is a hypothesis that ionizing radiation and some chemicals can promote chromosomal nondisjunction, but epidemiological evidence in trisomy 13 is not clear. No modifiable environmental risk factor is known to date. Therefore, the key to prevention is active prenatal screening and genetic counseling in advanced maternal age.
Trisomy 13 conceptions have a high frequency of spontaneous abortion, and the proportion surviving to birth is only a fraction of the conception frequency. Among first-trimester spontaneous abortions, trisomy 13 is one of the most common chromosomal abnormalities.
The karyotype of the meiotic nondisjunction type of trisomy 13 is 47,XX,+13 (female) or 47,XY,+13 (male). It is a complete trisomy in which chromosome 13 is present in three copies in all cells.
Chromosome 13 is one of the acrocentric chromosomes in the human genome and contains ribosomal RNA (rRNA) genes on its short arm (p arm). About 325 protein-coding genes are located on the long arm (q arm) of chromosome 13. In particular, important genes such as RB1 (retinoblastoma gene), BRCA2, and FOXO1 are located on chromosome 13. Overexpression of these genes due to the triplication is known to be involved in the various malformations of trisomy 13.
An important genetic characteristic that distinguishes trisomy 13 from Edwards syndrome (trisomy 18) is the high proportion of the translocation type (about 10~15%). This is because chromosome 13 is a major chromosome involved in Robertsonian translocations. Therefore, in every patient diagnosed with trisomy 13, it is essential to distinguish by karyotype analysis whether it is the complete type or the translocation type. When the translocation type is confirmed (Q91.6), parental karyotype analysis is required.
The meiotic nondisjunction type (Q91.4) mostly occurs sporadically with normal parental karyotypes. The recurrence risk is given as about 1% or the age-based risk, whichever is higher. When there is a history of a previous trisomy pregnancy, especially a trisomy of a chromosome other than 13, genetic counseling is provided considering germline mosaicism or a predisposition to nondisjunction.
Molecular genetic studies can analyze parental origin (maternal vs. paternal) and the stage of nondisjunction (MI vs. MII), which is used to understand the advanced maternal age effect and mechanism. Some studies also show that reduced recombination frequency is related to nondisjunction of chromosome 13.
The birth frequency of trisomy 13 (Patau syndrome) is about 1/5,000~1/12,000, lower than trisomy 18 (1/3,000~1/6,000). It is much rarer than Down syndrome (about 1/700~1/1,000). Worldwide, about 7,000~10,000 children with Patau syndrome are estimated to be born each year.
The sex distribution tends toward female predominance as in Edwards syndrome, but the difference is not as prominent as in Edwards syndrome. As for correlation with maternal age, the incidence increases greatly at age 35 or older, as in Edwards syndrome. The frequency in mothers under 30 is about 1/20,000, whereas it rises to about 1/1,000~1/2,000 at age 40 or older.
The frequency of spontaneous abortion in pregnancies with trisomy 13 conception is very high, so the conception frequency is much higher than the birth frequency. Trisomy 13 is found frequently in first-trimester spontaneous abortion samples. That is, a considerable number of trisomy 13 fetuses end in spontaneous abortion, and only some reach birth.
In Korea, based on National Health Insurance data and rare disease registration data, several dozen cases of Patau syndrome are registered each year. Since the introduction of NIPT, the prenatal diagnosis rate has improved, and the proportion diagnosed before birth is increasing relative to the proportion diagnosed after birth. In a survey of rare disease specialists in Korea as well, Patau syndrome is recognized, together with Edwards syndrome, as a major disease targeted by prenatal diagnosis research.
Differences in incidence by race are not as clear as for Down syndrome, but some studies report a slightly higher incidence in African American populations. This may be related to differences in maternal age distribution. The proportion of the translocation type of trisomy 13 (Q91.6) (about 10~15%) is known to show no significant difference between races.
The core pathogenesis of trisomy 13 is formation of the 47,+13 karyotype from meiotic nondisjunction of chromosome 13 and the resulting widespread gene dosage effect.
Meiotic nondisjunction: a diploid gamete is formed by a segregation error of the homologous chromosome pair of chromosome 13 (meiosis I) or of sister chromatids (meiosis II). Maternal-origin nondisjunction (about 70~80%) is the main route, and meiosis II nondisjunction is reported to be relatively more common than meiosis I. In advanced maternal age, decreased cohesin in the oocyte, errors in spindle-kinetochore attachment, and abnormal recombination patterns are involved.
Teratogenic mechanism of trisomy 13: Overexpression due to triplication of genes on chromosome 13 causes global developmental abnormalities. Holoprosencephaly, characteristic of Patau syndrome, is associated with abnormalities of genes involved in forebrain division. In particular, abnormal expression of genes in the ZIC2 and SHH signaling pathways is proposed to contribute to holoprosencephaly. However, a direct causal relationship between specific genes on chromosome 13 and specific malformations has not yet been fully elucidated.
Mechanism of facial malformations: Median facial malformations associated with holoprosencephaly (median facial cleft, cyclopia, proboscis) occur because forebrain and facial development are closely linked. Failure of midline division of the forebrain is accompanied by defective formation of midline facial structures.
Mechanism of polydactyly: Postaxial polydactyly, typically seen in Patau syndrome, is known to result from abnormalities in the distal signaling pathways of limb development, but which gene on chromosome 13 is directly involved is unclear.
Multisystem malformations such as cardiac malformations, renal malformations, and ocular malformations (microphthalmia, anophthalmia, retinal abnormalities) also arise from abnormal developmental pathways due to global overexpression of chromosome 13 genes. The prognosis of trisomy 13 is worse than that of trisomy 18 because the central nervous system malformation, holoprosencephaly, is more extensive and has a greater effect on functions essential for life.
Trisomy 13 (Patau syndrome) is characterized by more severe central nervous system and facial malformations than Edwards syndrome, and its pattern of multiple congenital malformations differs from that of Edwards syndrome.
Central nervous system malformations: Holoprosencephaly (HPE) is the most characteristic central nervous system malformation, occurring in about 50–70% of Patau syndrome cases. Holoprosencephaly is a malformation in which the forebrain (prosencephalon) fails to separate into left and right cerebral hemispheres, and is classified as alobar (complete non-separation of the forebrain, most severe), semilobar, and lobar (relatively mild). The alobar type is the most common in Patau syndrome. Microcephaly, agenesis of the corpus callosum, and Dandy-Walker malformation also accompany it. Central nervous system malformations are more severe than in Edwards syndrome, so the prognosis is worse.
Facial malformations: Median facial malformations associated with holoprosencephaly are characteristic. Cyclopia (fused orbits), proboscis (defective nose formation), median cleft lip, and monophthalmia may occur. Microphthalmia or anophthalmia is observed in about 50–70%. Cleft lip and cleft palate occur alone or in combination.
Polydactyly: Postaxial polydactyly is observed in about 60–80% and is the most characteristic limb finding of Patau syndrome. This contrasts with the overlapping fingers of Edwards syndrome. It can occur in both hands and feet.
Cardiovascular malformations: Congenital heart defects occur in about 80%. Ventricular septal defect (VSD), patent ductus arteriosus (PDA), atrial septal defect (ASD), and double outlet right ventricle are common. As in Edwards syndrome, cardiac malformations are one of the main causes of death.
Genitourinary malformations: Renal cysts (renal cortical cysts), hydronephrosis, and renal hypoplasia occur in about 50%. Cryptorchidism is common in boys.
Scalp defects (cutis aplasia): Localized scalp defects are observed in about 20–30% and are a relatively specific finding in Patau syndrome.
The physical examination findings of Patau syndrome (trisomy 13) include characteristic findings that distinguish it from Edwards syndrome.
Facial and head signs: Facial malformations related to holoprosencephaly are characteristic. Median cleft lip, cyclopia, proboscis, and microphthalmia or anophthalmia are observed. Microcephaly is common, and a prominent occiput is less characteristic than in Edwards syndrome. Low-set ears and malformed external ears are seen.
Scalp defects: Localized skin defects of the scalp (cutis aplasia/aplasia cutis congenita) are observed in about 20–30%, and this is a relatively specific finding in Patau syndrome.
Limb, hand, and foot signs: Postaxial polydactyly (extra fingers/toes on the little-finger side) is observed in 60–80% and is the representative limb finding of Patau syndrome. It is distinguished from the overlapping fingers of Edwards syndrome. Clubfoot or pes cavus may also occur.
Cardiac signs: Heart murmur, cyanosis, and signs of heart failure (tachypnea, hepatomegaly) are observed.
Muscle tone and neurological signs: Hypotonia or spasticity occurs. The sucking reflex is weak, and seizures occur. Apneic episodes are very common.
Prenatal ultrasound findings: Holoprosencephaly (fused orbits, single ventricle), microphthalmia, polydactyly, cardiac malformations, renal cysts, and growth retardation can be detected on prenatal ultrasound. Holoprosencephaly is a malformation that is detected relatively clearly on prenatal ultrasound and strongly suggests trisomy 13. However, because holoprosencephaly is not a finding unique to trisomy 13, karyotype analysis is required for confirmation.
Physical signs: Low birth weight and growth retardation are common. Decreased skin tension is observed. Hernias (umbilical hernia, inguinal hernia) may accompany.
Prenatal screening for Patau syndrome is included in the standard prenatal screening program together with Edwards syndrome.
Maternal serum screening (MSS): On the quad marker test (AFP, uE3, hCG, inhibin A), trisomy 13 shows a pattern in which AFP, uE3, and hCG are all decreased, similar to Edwards syndrome. However, the detection rate of serum screening for trisomy 13 is lower than for Edwards syndrome (about 50–70%). Because structural abnormalities such as holoprosencephaly are detected more clearly on ultrasound in trisomy 13, ultrasound findings play a more important role in screening than serum markers.
First-trimester screening: A combination of increased NT, decreased PAPP-A, and decreased β-hCG suggests trisomy 13. If fused orbits or holoprosencephaly are seen on first-trimester ultrasound, trisomy 13 should be suspected immediately.
NIPT (cfDNA): The sensitivity of NIPT for trisomy 13 is 98–99%, and the specificity is above 99%. However, compared with trisomy 18 or trisomy 21, caution is needed in interpreting results for trisomy 13 when the fetal fraction is low or mosaicism is present. A positive result must be confirmed by invasive karyotype analysis.
Prenatal ultrasound: When holoprosencephaly, fused orbits, microphthalmia, polydactyly, cardiac malformations, renal cysts, etc. are found, chromosomal abnormalities including trisomy 13 should be strongly suspected. Holoprosencephaly can be detected on prenatal ultrasound relatively early (from the end of the first trimester to the beginning of the second trimester).
Active screening of high-risk groups: NIPT or invasive diagnosis is actively recommended for mothers aged 35 or older, a history of a previous trisomy pregnancy, or ultrasound abnormalities (holoprosencephaly, polydactyly, etc.).
Confirmation of trisomy 13 (Patau syndrome) is made by cytogenetic or molecular genetic testing.
Standard G-banding karyotype analysis: Karyotype analysis is performed prenatally on CVS (11–14 weeks of gestation) or amniocentesis (15–20 weeks), and after birth on peripheral blood. It is essential to distinguish by karyotype analysis between 47,+13 (complete meiotic nondisjunction), the mosaic form (mos 47,+13/46), and the translocation form (46 chromosomes but with a chromosome 13 translocation). In the complete form (Q91.4), three copies of chromosome 13 are observed in all cells.
Distinguishing the complete and translocation forms: Because the translocation form accounts for about 10–15% of Patau syndrome, it is very important to clearly distinguish on karyotype analysis between the complete form (47,+13) and the translocation form (46 chromosomes with translocated chromosome 13 material). If the translocation form is confirmed, parental karyotype analysis is essential. This is one of the greatest clinical differences in the diagnosis of Patau syndrome and Edwards syndrome.
FISH: Rapid confirmation is possible by FISH using a chromosome 13-specific probe. It is used to provide preliminary prenatal results. Standard karyotype analysis is essential to distinguish the translocation form from the complete form.
Chromosomal microarray (CMA): Along with confirming the triplication, it detects additional genomic imbalances. It is useful for precisely defining the imbalanced region in the translocation form. When structural malformations accompany, CMA is additionally performed to supplement prognostic information.
Parental karyotype analysis: When the translocation form is confirmed, parental karyotype analysis must be performed to determine whether a parent is a carrier of a balanced Robertsonian translocation. Even in the meiotic nondisjunction form (Q91.4), confirmation of parental karyotype is recommended as standard counseling (to reconfirm that it is sporadic).
There is no fundamental treatment for Patau syndrome. As with Edwards syndrome, multidisciplinary supportive care is the mainstay of treatment, and an individualized approach is needed. However, because Patau syndrome includes a central nervous system malformation, holoprosencephaly, that is more severe than in Edwards syndrome, decisions on aggressive treatment are made even more carefully.
Neonatal intensive care: Management of apneic episodes, respiratory support, and cardiopulmonary stabilization are the priorities. Whether to use mechanical ventilation is decided considering the family's wishes and the clinical condition.
Treatment of cardiac malformations: As in Edwards syndrome, the indications for cardiac surgery are discussed. However, in Patau syndrome, severe neurological abnormalities due to holoprosencephaly accompany almost all cases, so there is a view that the benefit of cardiac surgery is more limited than in Edwards syndrome. Although studies supporting aggressive treatment in Patau syndrome have been increasing recently, individualized decisions are emphasized.
Seizure management: Because neonatal seizures are common, anticonvulsants such as phenobarbital and levetiracetam are used.
Nutritional support: Tube feeding is needed because of a weak sucking reflex and dysphagia. Gastrostomy is considered in long-term surviving children.
Palliative care and hospice: The palliative care team is involved early to provide family support, end-of-life planning, and psychosocial support. The role of palliative care in Patau syndrome is as central as in Edwards syndrome.
Surgical correction: Surgical correction of structural malformations such as cleft lip, cleft palate, and polydactyly is carefully individualized only when survival is expected.
The prognosis of trisomy 13 meiotic nondisjunction form (Q91.4) is worse than that of Edwards syndrome. The median survival is about 7–10 days, the 1-month survival rate is about 28–40%, and the 1-year survival rate is about 5–10%. Although similar to Edwards syndrome (1-year survival rate 5–10%), early mortality is higher in Patau syndrome because apneic episodes and central nervous system malformations are more extensive.
The main causes of death are apneic episodes, heart failure, respiratory failure, and central nervous system dysfunction. Because holoprosencephaly independently causes severe neurological damage, the neurological prognosis is very poor even if cardiac malformations are surgically corrected.
Long-term survival (1 year or more) occurs in about 5–10%, and these are mostly mosaic cases or cases with relatively mild holoprosencephaly (semilobar or lobar). Long-term survival is very rare in the complete meiotic nondisjunction form (Q91.4).
In surviving children with Patau syndrome, severe intellectual disability, seizures, growth failure, visual and hearing impairment, and recurrent respiratory infections remain persistent problems. Quality of life is severely reduced, and there is no capacity for independent living.
The main reason the prognosis of Patau syndrome is worse than that of Edwards syndrome is that the central nervous system malformation, holoprosencephaly, directly affects brainstem function essential for life.
Prevention of trisomy 13 meiotic nondisjunction form (Q91.4), as with the complete form of trisomy 18, is based on early identification of affected pregnancies through prenatal screening and genetic counseling.
Prenatal screening for advanced maternal age: Because the risk of Patau syndrome increases in mothers aged 35 or older, NIPT or invasive diagnosis is actively recommended. When planning a pregnancy at advanced maternal age, the risk of trisomies including Patau syndrome is counseled.
Optimizing the prenatal screening program: NIPT is used cost-effectively to screen simultaneously for trisomy 13, trisomy 18, and trisomy 21. When findings specific to trisomy 13, such as holoprosencephaly or polydactyly, are found on ultrasound, invasive testing is recommended immediately.
PGT-A: In assisted reproduction, implantation of trisomy 13 embryos can be prevented through PGT-A.
Genetic counseling: To parents who have delivered a child with Patau syndrome, the recurrence risk (about 1% or the age-based risk, whichever is higher) is explained, and appropriate prenatal diagnosis options are presented according to the karyotype result (complete form or translocation form). When the translocation form (Q91.6) is confirmed, parental karyotype analysis is essential, and it is counseled that the recurrence risk increases substantially if a carrier of a balanced Robertsonian translocation is identified.